Know Cancer

or
forgot password

A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life


N/A
21 Years
80 Years
Open (Enrolling)
Both
Newly Diagnosed Breast Cancer, Newly Diagnosed Colon Cancer, Newly Diagnosed Lung Cancer

Thank you

Trial Information

A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life


Inclusion Criteria:



- fluent in English, Spanish, or Mandarin

- between the ages of 21-80 years old

- In the Investigator's judgment, participants must have satisfactory cognitive
function to provide valid informed consent and participate in the ICCAN intervention.
The Blessed Orientation-Memory Concentration test (BOMC) will be used as a cognitive
screening tool. Patients must have a BOMC score of less than or equal to 11.

- has a new diagnosis of either breast, colon or lung cancer (diagnosed within the past
month) currently receiving chemotherapy (started within the past month) and/or
radiation therapy (started within the past week), or

- scheduled to begin chemotherapy and/or radiation therapy within the next 2 months
(excluding surgery only patients)

- planning on remaining in the area for at least 1 year

Exclusion Criteria:

- diagnosed with Stage IV disease

- presence of cognitive impairment disorder (e.g., delirium or dementia) sufficient to
preclude meaningful informed consent and/or data collection. (BOMC >11).

- has another family member already enrolled in ICCAN (as determined by patient report)

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Treatment completion/adherence

Outcome Description:

The primary outcome, cancer treatment completion, will be determined by chart review at 3, 6, and 12 months after enrollment.

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Francesca Gany, MD, MS

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

12-223

NCT ID:

NCT01742143

Start Date:

November 2012

Completion Date:

November 2014

Related Keywords:

  • Newly Diagnosed Breast Cancer
  • Newly Diagnosed Colon Cancer
  • Newly Diagnosed Lung Cancer
  • Quality of life
  • lung
  • breast
  • colon
  • 12-223
  • Breast Neoplasms
  • Colonic Neoplasms
  • Lung Neoplasms

Name

Location

Memorial Sloan-Kettering Cancer CenterNew York, New York  10021
Lutheran Medical CenterBrooklyn, New York  11220
Ralph Lauren Center for Cancer Care and PreventionNew York, New York  10035
Lincoln HospitalBronx, New York  10451